CR20240120A - Compuesto inductor de la degradación de PLK1 novedoso - Google Patents
Compuesto inductor de la degradación de PLK1 novedosoInfo
- Publication number
- CR20240120A CR20240120A CR20240120A CR20240120A CR20240120A CR 20240120 A CR20240120 A CR 20240120A CR 20240120 A CR20240120 A CR 20240120A CR 20240120 A CR20240120 A CR 20240120A CR 20240120 A CR20240120 A CR 20240120A
- Authority
- CR
- Costa Rica
- Prior art keywords
- plk1
- degradation
- novel
- inducing compound
- present disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente divulgación se refiere a un compuesto inductor de la degradación de PLK1 novedoso, a un método para preparar el mismo y al uso del mismo. Los compuestos de la presente divulgación exhiben un efecto de inducción de la degradación de PLK1. Por lo tanto, los compuestos de la presente divulgación pueden utilizarse eficazmente para prevenir o tratar enfermedades relacionadas con PLK1.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210105358 | 2021-08-10 | ||
| KR20210106488 | 2021-08-12 | ||
| KR20210117389 | 2021-09-03 | ||
| KR20210126757 | 2021-09-24 | ||
| KR20220008456 | 2022-01-20 | ||
| KR20220020996 | 2022-02-17 | ||
| KR20220054880 | 2022-05-03 | ||
| KR20220075838 | 2022-06-21 | ||
| PCT/KR2022/011961 WO2023018236A1 (en) | 2021-08-10 | 2022-08-10 | Novel plk1 degradation inducing compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240120A true CR20240120A (es) | 2024-05-22 |
Family
ID=85200656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240120A CR20240120A (es) | 2021-08-10 | 2022-08-10 | Compuesto inductor de la degradación de PLK1 novedoso |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20250114460A1 (es) |
| EP (4) | EP4384521A4 (es) |
| JP (4) | JP7555156B2 (es) |
| KR (5) | KR102604801B1 (es) |
| CN (2) | CN116261458B (es) |
| AU (1) | AU2022327025A1 (es) |
| CA (1) | CA3228601A1 (es) |
| CL (1) | CL2024000373A1 (es) |
| CO (1) | CO2024001256A2 (es) |
| CR (1) | CR20240120A (es) |
| EC (1) | ECSP24010109A (es) |
| IL (1) | IL310678A (es) |
| MX (1) | MX2024001774A (es) |
| PE (1) | PE20240894A1 (es) |
| WO (5) | WO2023018238A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210122164A (ko) * | 2020-03-27 | 2021-10-08 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물 |
| PY2269135A (es) | 2021-08-10 | 2024-01-29 | Ifm Due Inc | Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting |
| CN120603831A (zh) * | 2022-11-29 | 2025-09-05 | 厄普特拉株式会社 | 具有增加的刚性的plk1降解诱导化合物 |
| JP2025530757A (ja) * | 2023-02-02 | 2025-09-17 | オップテラ インコーポレイテッド | 新規ｐｌｋ１分解誘導化合物 |
| KR20250167154A (ko) * | 2023-03-10 | 2025-11-28 | 글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. | 신규한 e3유비퀴틴 리가제 리간드, 단백질 분해제 및 이의 응용 |
| AU2024286124A1 (en) | 2023-06-08 | 2025-12-18 | Nurix Therapeutics, Inc. | Bifunctional azines conjogates as selective degraders of smarca2 and therapeutic uses thereof |
| CN121816348A (zh) | 2023-08-11 | 2026-04-07 | 深圳众格生物科技有限公司 | 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用 |
| CN117126133A (zh) * | 2023-08-14 | 2023-11-28 | 中国海洋大学 | 一种化合物及其用途 |
| WO2025062330A1 (en) | 2023-09-20 | 2025-03-27 | Aurigene Oncology Limited | Heterocyclic compounds as cbp selective degraders |
| US20250197411A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2025239662A1 (ko) * | 2024-05-13 | 2025-11-20 | (주) 업테라 | 분해 약물-항체 접합체용 plk1 분해 유도 화합물 |
| CN118724841A (zh) * | 2024-06-14 | 2024-10-01 | 南通华祥医药科技有限公司 | 一种n-氨基哌啶二盐酸盐的制备方法 |
| WO2026013577A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026013576A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Dihydrouracil derivatives useful for the targeted degradation of vav1 |
| WO2026026773A1 (zh) * | 2024-07-29 | 2026-02-05 | 杭州胶联生物医药科技有限公司 | 作为vav1蛋白靶点降解剂的新型取代杂环类化合物 |
| CN121591699A (zh) * | 2024-08-22 | 2026-03-03 | 武汉人福创新药物研发中心有限公司 | 作为vav1降解剂的苯并杂环类化合物及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200808805A (en) * | 2006-04-12 | 2008-02-16 | Vertex Pharma | Tetrahydropteridines useful as inhibitors of protein kinases |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| JP5087640B2 (ja) | 2007-03-22 | 2012-12-05 | 武田薬品工業株式会社 | Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2016349781A1 (en) * | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| CN106543185B (zh) * | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| EP3577109A4 (en) * | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| CN106977584B (zh) | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| WO2020023851A1 (en) | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| CN109879877B (zh) * | 2019-03-04 | 2021-08-10 | 吉林大学 | 一种可降解plk1和brd4蛋白的化合物及其应用 |
| CN114521196A (zh) | 2019-09-16 | 2022-05-20 | 诺华股份有限公司 | 双官能团降解剂及其使用方法 |
| EP4034132B1 (en) * | 2019-09-27 | 2026-02-25 | Dana-Farber Cancer Institute, Inc. | Erk5 degraders as therapeutics in cancer and inflammatory diseases |
| KR20210122164A (ko) * | 2020-03-27 | 2021-10-08 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물 |
-
2022
- 2022-08-10 KR KR1020227036557A patent/KR102604801B1/ko active Active
- 2022-08-10 KR KR1020247013823A patent/KR20240060721A/ko active Pending
- 2022-08-10 CN CN202280006544.1A patent/CN116261458B/zh active Active
- 2022-08-10 JP JP2023514160A patent/JP7555156B2/ja active Active
- 2022-08-10 JP JP2024507883A patent/JP2024530495A/ja active Pending
- 2022-08-10 WO PCT/KR2022/011963 patent/WO2023018238A1/en not_active Ceased
- 2022-08-10 CR CR20240120A patent/CR20240120A/es unknown
- 2022-08-10 EP EP22856233.6A patent/EP4384521A4/en active Pending
- 2022-08-10 KR KR1020227046443A patent/KR102662205B1/ko active Active
- 2022-08-10 PE PE2024000208A patent/PE20240894A1/es unknown
- 2022-08-10 KR KR1020227036596A patent/KR102604802B1/ko active Active
- 2022-08-10 CN CN202280006505.1A patent/CN116322700B/zh active Active
- 2022-08-10 US US18/580,553 patent/US20250114460A1/en active Pending
- 2022-08-10 WO PCT/IB2022/057471 patent/WO2023017442A1/en not_active Ceased
- 2022-08-10 MX MX2024001774A patent/MX2024001774A/es unknown
- 2022-08-10 US US18/019,047 patent/US11912710B2/en active Active
- 2022-08-10 EP EP22808930.6A patent/EP4157849A4/en active Pending
- 2022-08-10 JP JP2023514149A patent/JP7555155B2/ja active Active
- 2022-08-10 EP EP22855629.6A patent/EP4384520A4/en active Pending
- 2022-08-10 EP EP22808931.4A patent/EP4157850A4/en active Pending
- 2022-08-10 WO PCT/KR2022/011961 patent/WO2023018236A1/en not_active Ceased
- 2022-08-10 WO PCT/IB2022/057475 patent/WO2023017446A1/en not_active Ceased
- 2022-08-10 US US18/580,506 patent/US20250101025A1/en active Pending
- 2022-08-10 AU AU2022327025A patent/AU2022327025A1/en active Pending
- 2022-08-10 WO PCT/KR2022/011962 patent/WO2023018237A1/en not_active Ceased
- 2022-08-10 US US18/019,034 patent/US11939334B2/en active Active
- 2022-08-10 CA CA3228601A patent/CA3228601A1/en active Pending
- 2022-08-10 KR KR1020227042318A patent/KR102604803B1/ko active Active
- 2022-08-10 IL IL310678A patent/IL310678A/en unknown
- 2022-08-10 JP JP2024507884A patent/JP2024530195A/ja active Pending
-
2024
- 2024-02-06 CO CONC2024/0001256A patent/CO2024001256A2/es unknown
- 2024-02-06 CL CL2024000373A patent/CL2024000373A1/es unknown
- 2024-02-07 EC ECSENADI202410109A patent/ECSP24010109A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001256A2 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2020011495A (es) | Inhibidores de bcl-2. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| EA202092248A1 (ru) | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| BR112017019287A2 (pt) | composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| CL2020002157A1 (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CO2021001219A2 (es) | Benzimidazoles sustituidos como inhibidores de pad4 | |
| EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| BR112023023578A2 (pt) | Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda | |
| JOP20250215A1 (ar) | ثيازولو[4،5-d]-بيريميدين-7-ونات كمثبطات NOX4 | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
| EA202192288A1 (ru) | Соединения на основе нейрегулина-4 и способы их применения | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| MY205651A (en) | Agent for treating latex-producing plant |